Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension
- PMID: 16868809
- DOI: 10.1007/s00535-006-1809-y
Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension
Abstract
Portopulmonary hypertension is a recognized but uncommon complication of cirrhosis. Liver transplantation may be contraindicated in patients with severe portopulmonary hypertension. In order to decrease the pulmonary arterial pressure, intravenous administration of epoprostenol has been shown to provide substantial beneficial results in these patients. Additionally, a recent case report demonstrated that long-term oral administration of sildenafil decreased pulmonary arterial pressure, but its effects on splanchnic hemodynamics were not measured. We report on a patient with cirrhosis and portopulmonary hypertension and the changes in the hemodynamic status after an oral administration of sildenafil. This case report clearly delineates that sildenafil decreases pulmonary arterial pressure but may exacerbate portal hypertension and hyperdynamic circulation in patients with cirrhosis and portopulmonary hypertension.
Similar articles
-
Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil.Liver Transpl. 2006 Apr;12(4):690-1. doi: 10.1002/lt.20748. Liver Transpl. 2006. PMID: 16555327 No abstract available.
-
Novel use of sildenafil in the treatment of portopulmonary hypertension.J Heart Lung Transplant. 2005 Apr;24(4):498-500. doi: 10.1016/j.healun.2004.01.017. J Heart Lung Transplant. 2005. PMID: 15797756
-
Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension.Turk J Gastroenterol. 2014 Aug;25(4):429-32. doi: 10.5152/tjg.2014.7688. Turk J Gastroenterol. 2014. PMID: 25254528
-
[Pulmonary hypertension complicating portal hypertension: portopulmonary hypertension].Nihon Rinsho. 2001 Jun;59(6):1186-92. Nihon Rinsho. 2001. PMID: 11411134 Review. Japanese.
-
Portopulmonary hypertension: short review.Eur J Gastroenterol Hepatol. 2010 Apr;22(4):385-90. doi: 10.1097/MEG.0b013e3283337130. Eur J Gastroenterol Hepatol. 2010. PMID: 19907338 Review.
Cited by
-
Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver.BMC Gastroenterol. 2009 Sep 18;9:69. doi: 10.1186/1471-230X-9-69. BMC Gastroenterol. 2009. PMID: 19765284 Free PMC article.
-
Extracellular vesicles from mesenchymal stem cells reduce neuroinflammation in hippocampus and restore cognitive function in hyperammonemic rats.J Neuroinflammation. 2023 Jan 2;20(1):1. doi: 10.1186/s12974-022-02688-4. J Neuroinflammation. 2023. PMID: 36593485 Free PMC article.
-
Circulating endotoxin and interleukin-6 levels are associated with Doppler-evaluated pulmonary vascular resistance in cirrhotic patients.Hepatol Int. 2012 Oct;6(4):783-9. doi: 10.1007/s12072-011-9337-0. Epub 2012 Feb 2. Hepatol Int. 2012. PMID: 26201526
-
Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report.J Med Case Rep. 2007 Jul 10;1:46. doi: 10.1186/1752-1947-1-46. J Med Case Rep. 2007. PMID: 17623085 Free PMC article.
-
Sildenafil does not have a significant effect on the portal vein velocity, cross-sectional area, and congestion index in the dog.Front Vet Sci. 2022 Jul 19;9:920423. doi: 10.3389/fvets.2022.920423. eCollection 2022. Front Vet Sci. 2022. PMID: 35928120 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical